Larivin Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.50 M
- Paid Up Capital ₹ 0.60 M
- Company Age 1 Year 7 Months
- Open Charges ₹ 3.77 Cr
About Larivin Pharma
Larivin Pharma Private Limited (LPPL) is a Private Limited Indian Non-Government Company incorporated in India on 04 July 2023 (One year and seven months 21 days old ). Its registered office is in Tiruvallur, Tamil Nadu, India.
The Company is engaged in the Paper Industry.
The Company's status is Active It's a company limited by shares with an authorized capital of Rs 1.50 M and a paid-up capital of Rs 0.60 M.
The company currently has active open charges totaling ₹3.77 Cr.
Ramaiyan Natesavalavan, Saravanan Nambiyappan, Kumaralingam Sujatha, and One other member serve as directors at the Company.
Company Details
- Location
Tiruvallur, Tamil Nadu, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U21001TN2023PTC161631
- Company No.
161631
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
04 Jul 2023
- Date of AGM
-
- Date of Balance Sheet
-
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Who are the key members and board of directors at Larivin Pharma?
Board Members (4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Ramaiyan Natesavalavan  | Director | 04-Jul-2023 | Current |
| Saravanan Nambiyappan | Director | 04-Jul-2023 | Current |
| Kumaralingam Sujatha | Director | 14-May-2024 | Current |
| Natesavalavan Monalisa | Director | 14-May-2024 | Current |
Financial Performance of Larivin Pharma.
Enhance accessibility to Larivin Pharma's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Larivin Pharma?
Unlock access to Larivin Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Larion Life Sciences Private LimitedRamaiyan Natesavalavan and Saravanan Nambiyappan are mutual person
Charges (Loans)
₹37.74 M
₹0
Charges Breakdown by Lending Institutions
- Others : 3.77 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 05 Jul 2024 | Others | ₹3.77 Cr | Open |
How Many Employees Work at Larivin Pharma?
Unlock and access historical data on people associated with Larivin Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Larivin Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Larivin Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.